With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

We are excited to welcome Steve to Phathom during this important growth period for our Company,” said Michael Cola, Chairman of Phathom. “Steve is an accomplished biopharmaceutical leader with a ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...